January 2024 - Page 218 of 272

NASDAQ Companies - January 5, 2024

Compass Therapeutics Provides Corporate Update

We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x […]

NYSE Companies - January 5, 2024

Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment

Mayo Clinic’s PSMA Alpha-PET DoubLET platform allows for imaging and targeted therapy with alpha and/or beta-particle radiopharmaceutical therapy (RPT) using […]

NYSE Companies - January 5, 2024

Greif Announces Price Increase for Uncoated Recycled Paperboard (URB), Tube and Core and Protective Packaging Products

DELAWARE, Ohio, Jan. 05, 2024 (GLOBE NEWSWIRE) — Greif, Inc. (NYSE: GEF, GEF.B), a world leader in industrial packaging products […]

NASDAQ Companies - January 5, 2024

CervoMed to Participate in the Emerging Growth Conference 66

BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for […]

NASDAQ Companies - January 5, 2024

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel […]

NASDAQ Companies - January 5, 2024

Lifecore Biomedical Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements

Lifecore enters into commercial agreements with Alcon that include new 8-year commercial manufacturing arrangements Lifecore receives amendment and waiver for […]

NASDAQ Companies - January 5, 2024

Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement

MELBOURNE, Australia, Jan. 05, 2024 (GLOBE NEWSWIRE) — Genetic Technologies Limited (NASDAQ: GENE, “Company”) a global leader in genomics-based tests […]